Unicycive Therapeutics, Inc.
General ticker "UNCY" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
Unicycive Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -5.5%.
Estimated limits based on current volatility of 3.2%: low 3.47$, high 3.70$
Factors to consider:
- Total employees count: 21 (-4.5%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Uncertain profitability, FDA approval delays, Regulatory and compliance, Market competition, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.18$, 8.35$]
- 2026-12-31 to 2027-12-31 estimated range: [2.70$, 7.32$]
Financial Metrics affecting the UNCY estimates:
- Negative: with PPE of -2.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Positive: -18.95 < Investing cash flow per share per price, % of -13.06
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: 58.56 < Shareholder equity ratio, % of 61.46 <= 69.38
- Positive: Inventory ratio change, % of 0 <= 0
Short-term UNCY quotes
Long-term UNCY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.68MM | $0.00MM | $0.00MM |
| Operating Expenses | $21.45MM | $32.12MM | $29.52MM |
| Operating Income | $-20.77MM | $-32.12MM | $-29.52MM |
| Non-Operating Income | $-9.77MM | $-4.61MM | $2.96MM |
| Interest Expense | $0.08MM | $0.07MM | $0.07MM |
| R&D Expense | $12.90MM | $20.01MM | $9.12MM |
| Income(Loss) | $-30.54MM | $-36.73MM | $-26.56MM |
| Net Income(Loss)* | $-30.54MM | $-36.73MM | $-26.55MM |
| Stockholders Equity | $-3.81MM | $7.43MM | $30.20MM |
| Assets | $14.19MM | $31.67MM | $49.13MM |
| Operating Cash Flow | $-18.28MM | $-28.57MM | $-31.32MM |
| Capital expenditure | $0.01MM | $0.07MM | $0.02MM |
| Investing Cash Flow | $-0.01MM | $-0.07MM | $-12.10MM |
| Financing Cash Flow | $27.54MM | $45.09MM | $46.47MM |
| Earnings Per Share** | $-12.45 | $-5.48 | $-1.67 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.